BACKGROUND: Induction with lymphocyte-depleting antibodies is routinely used to prevent rejection but often skews T cells toward memory. It is not fully understood which memory and regulatory T-cell subsets are most affected and how they relate to clinical outcomes. METHODS: We analyzed T cells from 57 living-donor renal transplant recipients (12 reactive and 45 quiescent) 2.8±1.4 years after alemtuzumab induction. Thirty-four healthy subjects and nine patients with acute cellular rejection (ACR) were also studied. RESULTS: We found that alemtuzumab caused protracted CD4 more than CD8 T-lymphocyte deficiency, increased proportion of CD4 memory T cells, and decreased proportion of CD4 regulatory T cells. Reactive patients exhibited higher proportions of CD4 effector memory T cells (TEM) and CD8 terminally differentiated TEM (TEMRA), with greater CD4 TEM and CD8 TEMRA to regulatory T cell ratios, than quiescent patients or healthy controls. Patients with ongoing ACR had profound reduction in circulating CD8 TEMRA. Mixed lymphocyte assays showed significantly lower T-cell proliferation to donor than third-party antigens in the quiescent group, while reactive and ACR patients exhibited increased effector molecules in CD8 T cells. CONCLUSIONS: Our findings provide evidence that T-cell skewing toward TEM may be associated with antigraft reactivity long after lymphodepletion. Further testing of TEM and TEMRA subsets as rejection predictors is warranted.
BACKGROUND: Induction with lymphocyte-depleting antibodies is routinely used to prevent rejection but often skews T cells toward memory. It is not fully understood which memory and regulatory T-cell subsets are most affected and how they relate to clinical outcomes. METHODS: We analyzed T cells from 57 living-donor renal transplant recipients (12 reactive and 45 quiescent) 2.8±1.4 years after alemtuzumab induction. Thirty-four healthy subjects and nine patients with acute cellular rejection (ACR) were also studied. RESULTS: We found that alemtuzumab caused protracted CD4 more than CD8T-lymphocyte deficiency, increased proportion of CD4 memory T cells, and decreased proportion of CD4 regulatory T cells. Reactive patients exhibited higher proportions of CD4 effector memory T cells (TEM) and CD8 terminally differentiated TEM (TEMRA), with greater CD4 TEM and CD8TEMRA to regulatory T cell ratios, than quiescent patients or healthy controls. Patients with ongoing ACR had profound reduction in circulating CD8TEMRA. Mixed lymphocyte assays showed significantly lower T-cell proliferation to donor than third-party antigens in the quiescent group, while reactive and ACR patients exhibited increased effector molecules in CD8 T cells. CONCLUSIONS: Our findings provide evidence that T-cell skewing toward TEM may be associated with antigraft reactivity long after lymphodepletion. Further testing of TEM and TEMRA subsets as rejection predictors is warranted.
Authors: Kumiko Isse; Kedar Grama; Isaac Morse Abbott; Andrew Lesniak; John G Lunz; William M F Lee; Susan Specht; Natasha Corbitt; Yoshiaki Mizuguchi; Badrinath Roysam; A J Demetris Journal: Clin Liver Dis Date: 2010-11 Impact factor: 6.126
Authors: C Macedo; E A Orkis; I Popescu; B D Elinoff; A Zeevi; R Shapiro; F G Lakkis; D Metes Journal: Am J Transplant Date: 2009-07-16 Impact factor: 8.086
Authors: L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio Journal: Am J Transplant Date: 2011-05-12 Impact factor: 8.086
Authors: S Gurkan; Y Luan; N Dhillon; S R Allam; T Montague; J S Bromberg; S Ames; S Lerner; Z Ebcioglu; V Nair; R Dinavahi; V Sehgal; P Heeger; B Schroppel; B Murphy Journal: Am J Transplant Date: 2010-09 Impact factor: 8.086
Authors: Giuseppe Orlando; Peiman Hematti; Robert J Stratta; George W Burke; Pierpaolo Di Cocco; Pierpaolo Di Cocco; Francesco Pisani; Shay Soker; Kathryn Wood Journal: Ann Surg Date: 2010-12 Impact factor: 12.969
Authors: Alan C Farney; William Doares; Jeffrey Rogers; Rajinder Singh; Erica Hartmann; Lois Hart; Elizabeth Ashcraft; Amber Reeves-Daniels; Michael Gautreaux; Samy S Iskandar; Phillip Moore; Patricia L Adams; Robert J Stratta Journal: Transplantation Date: 2009-09-27 Impact factor: 4.939
Authors: H P Tan; J Donaldson; A Basu; M Unruh; P Randhawa; V Sharma; C Morgan; J McCauley; C Wu; N Shah; A Zeevi; R Shapiro Journal: Am J Transplant Date: 2008-12-15 Impact factor: 8.086
Authors: M R L Marco; E M Dons; D J van der Windt; J K Bhama; L T Lu; A F Zahorchak; F G Lakkis; D K C Cooper; M B Ezzelarab; A W Thomson Journal: Transpl Immunol Date: 2013-10-09 Impact factor: 1.708
Authors: Sarah Nikiforow; Haesook T Kim; Bhavjot Bindra; Sean McDonough; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent T Ho; Edwin P Alyea; Bruce R Blazar; Jerome Ritz; Robert J Soiffer; Joseph H Antin; Corey S Cutler Journal: Biol Blood Marrow Transplant Date: 2013-02-14 Impact factor: 5.742
Authors: Kumiko Isse; Andrew Lesniak; Kedar Grama; John Maier; Susan Specht; Marcela Castillo-Rama; John Lunz; Badrinath Roysam; George Michalopoulos; Anthony J Demetris Journal: Hepatology Date: 2013-03-19 Impact factor: 17.425
Authors: E M Dons; G Raimondi; H Zhang; A F Zahorchak; J K Bhama; L Lu; M Ezzelarab; J N M Ijzermans; D K C Cooper; A W Thomson Journal: Am J Transplant Date: 2013-05-01 Impact factor: 8.086